Mirikizumab for moderate to severe ulcerative colitis

Abstract

Mirikizumab (Omvoh) is an anti‐IL‐23 monoclonal antibody for the treatment of moderate to severe ulcerative colitis. This article outlines its administration, clinical trial efficacy, adverse effects and place in therapy.